• Something wrong with this record ?

Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results

B. Tombal, M. Borre, P. Rathenborg, P. Werbrouck, H. Van Poppel, A. Heidenreich, P. Iversen, J. Braeckman, J. Heracek, B. Baron, A. Krivoshik, M. Hirmand, MR. Smith,

. 2018 ; 199 (2) : 459-464. [pub] 20170901

Language English Country United States

Document type Clinical Trial, Phase II, Journal Article, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc19028751

PURPOSE: A phase 2 study of enzalutamide monotherapy in patients with hormone naïve prostate cancer demonstrated high prostate specific antigen response rates at 25 weeks, 1 year and 2 years with minimal effects on total body bone mineral density and favorable safety. In this followup analysis we evaluated enzalutamide antitumor activity and safety at 3 years. MATERIALS AND METHODS: In a single arm analysis 67 patients with hormone naïve prostate cancer and noncastrate testosterone (230 ng/dl or greater) received enzalutamide 160 mg per day orally until disease progression or unacceptable toxicity. The primary end point was the prostate specific antigen response (80% or greater decline from baseline). RESULTS: No patients discontinued treatment during year 3. Of 42 patients with prostate specific antigen assessments at 3 years 38 (90.5%, 95% CI 77.4-97.3) maintained a prostate specific antigen response. Of 26 patients with metastases at baseline 17 (65.4%) had a complete or partial response as the best overall response during 3 years. In patients who completed the 3-year visit minimal mean changes from baseline were observed in total body bone mineral density or bone mineral density of the femoral neck, trochanter, spine L1-L4 or forearm (range -2.7% to -0.1%). At 3 years total body fat had increased a mean of 16.5%, total lean body mass had decreased a mean of -6.5% and global health status had minimally decreased from baseline. Common adverse events were gynecomastia, fatigue, hot flush and nipple pain. CONCLUSIONS: Enzalutamide antitumor activity was maintained in patients with hormone naïve prostate cancer at 3 years. Overall bone mineral density, global health status and safety results were similar to those at 2 years.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028751
003      
CZ-PrNML
005      
20190819100951.0
007      
ta
008      
190813s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.juro.2017.08.103 $2 doi
035    __
$a (PubMed)28867562
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Tombal, Bertrand $u Cliniques universitaires Saint-Luc, Brussels, Belgium. Electronic address: bertrand.tombal@uclouvain.be.
245    10
$a Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results / $c B. Tombal, M. Borre, P. Rathenborg, P. Werbrouck, H. Van Poppel, A. Heidenreich, P. Iversen, J. Braeckman, J. Heracek, B. Baron, A. Krivoshik, M. Hirmand, MR. Smith,
520    9_
$a PURPOSE: A phase 2 study of enzalutamide monotherapy in patients with hormone naïve prostate cancer demonstrated high prostate specific antigen response rates at 25 weeks, 1 year and 2 years with minimal effects on total body bone mineral density and favorable safety. In this followup analysis we evaluated enzalutamide antitumor activity and safety at 3 years. MATERIALS AND METHODS: In a single arm analysis 67 patients with hormone naïve prostate cancer and noncastrate testosterone (230 ng/dl or greater) received enzalutamide 160 mg per day orally until disease progression or unacceptable toxicity. The primary end point was the prostate specific antigen response (80% or greater decline from baseline). RESULTS: No patients discontinued treatment during year 3. Of 42 patients with prostate specific antigen assessments at 3 years 38 (90.5%, 95% CI 77.4-97.3) maintained a prostate specific antigen response. Of 26 patients with metastases at baseline 17 (65.4%) had a complete or partial response as the best overall response during 3 years. In patients who completed the 3-year visit minimal mean changes from baseline were observed in total body bone mineral density or bone mineral density of the femoral neck, trochanter, spine L1-L4 or forearm (range -2.7% to -0.1%). At 3 years total body fat had increased a mean of 16.5%, total lean body mass had decreased a mean of -6.5% and global health status had minimally decreased from baseline. Common adverse events were gynecomastia, fatigue, hot flush and nipple pain. CONCLUSIONS: Enzalutamide antitumor activity was maintained in patients with hormone naïve prostate cancer at 3 years. Overall bone mineral density, global health status and safety results were similar to those at 2 years.
650    _2
$a aplikace orální $7 D000284
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protinádorové látky $x škodlivé účinky $x terapeutické užití $7 D000970
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a fenylthiohydantoin $x škodlivé účinky $x analogy a deriváty $x terapeutické užití $7 D010669
650    _2
$a nádory prostaty $x farmakoterapie $7 D011471
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Borre, Michael $u Aarhus University Hospital, Aarhus, Denmark.
700    1_
$a Rathenborg, Per $u Herlev Hospital, Herlev, Denmark.
700    1_
$a Werbrouck, Patrick $u AZ Groeninge Kortrijk, Kortrijk, Belgium.
700    1_
$a Van Poppel, Hendrik $u Universitair ziekenhuis Leuven, Leuven, Belgium.
700    1_
$a Heidenreich, Axel $u Cologne University, Cologne, Germany.
700    1_
$a Iversen, Peter $u Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
700    1_
$a Braeckman, Johan $u Universitair ziekenhuis Brussels, Brussels, Belgium.
700    1_
$a Heracek, Jiri $u Univerzita Karlova v Praze, Prague, Czech Republic.
700    1_
$a Baron, Benoit $u Astellas Pharma, Inc., Leiden, The Netherlands.
700    1_
$a Krivoshik, Andrew $u Astellas Pharma, Inc., Northbrook, Illinois.
700    1_
$a Hirmand, Mohammad $u Medivation, Inc., San Francisco, California.
700    1_
$a Smith, Matthew R $u Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
773    0_
$w MED00003040 $t The Journal of urology $x 1527-3792 $g Roč. 199, č. 2 (2018), s. 459-464
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28867562 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190819101225 $b ABA008
999    __
$a ok $b bmc $g 1433900 $s 1067211
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 199 $c 2 $d 459-464 $e 20170901 $i 1527-3792 $m The Journal of urology $n J Urol $x MED00003040
LZP    __
$a Pubmed-20190813

Find record

Citation metrics

Archiving options